What does Nuvectis Pharma, Inc. do?
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the…
What is Nuvectis Pharma, Inc.'s P/E and P/B ratio?
Nuvectis Pharma, Inc. has a P/E ratio of -15.9 and a P/B ratio of 75.09.
What is Nuvectis Pharma, Inc.'s debt-to-equity ratio?
Nuvectis Pharma, Inc. has a debt-to-equity ratio of 0.00.
How much does Nuvectis Pharma, Inc. owe compared with what it owns?
Nuvectis Pharma, Inc. owes $0.59 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Nuvectis Pharma, Inc.'s Positivity rank?
Nuvectis Pharma, Inc. is ranked #6,336 of 6,774 companies globally and #3,619 of 4,000 in United States on PositoAI, with a Positivity Score of -15,750.
Does Nuvectis Pharma, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Nuvectis Pharma, Inc..
Where can I read the latest news about Nuvectis Pharma, Inc.?
Recent headlines about Nuvectis Pharma, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Nuvectis Pharma, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Nuvectis Pharma, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.